AstraZeneca PLC (AZN)vsBrainsway Ltd (BWAY)
AZN
AstraZeneca PLC
$184.45
-0.23%
HEALTHCARE · Cap: $293.73B
BWAY
Brainsway Ltd
$9.39
-7.12%
HEALTHCARE · Cap: $406.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 102683% more annual revenue ($62.38B vs $60.70M). AZN leads profitability with a 17.7% profit margin vs 15.6%. AZN trades at a lower P/E of 26.8x. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
BWAY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$184.45
$13.49 discount
Intrinsic value data unavailable for BWAY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Revenue surging 35.4% year-over-year
Earnings expanding 59.8% YoY
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while BWAY is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.15 — expect wider price swings.
BWAY is growing revenue faster at 35.4% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 51/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?